Let's check to see if these gains by the biotech can be sustained.
Let's size up the prospects for treatments and the shares.
BIIB shares have jumped around 50% in early trading activity Wednesday.
After a deal with GlaxoSmithKline, the small-cap antibiotic developer Spero Therapeutics should get a shot as an options play.
Shares of Novavax are looking weak and in need of a booster, according to the technicals.
Let's look at the charts and indicators.
This biopharmaceutical firm shows promise.
There are still pockets of strength if you're willing to dig deep, though it's crucial to have crystal-clear stop levels to avert serious losses.
These recently downgraded names are displaying both quantitative and technical deterioration.
The charts give us an answer.